Teva Pharmaceutical Industries layoffs, on the record
Every job cut, severance charge and restructuring Teva Pharmaceutical Industries reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from 36,830 to 33,950.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2024 | 36,830 | December 31, 2024 |
| 10-K for 2025 | 33,950 | December 31, 2025 |
Job cuts, severance and restructuring
Our summaryThe filing describes closing or divesting a significant number of manufacturing plants in the United States, Europe, Israel, Japan and India under a restructuring plan.
Word for word“In recent years, we have closed or divested a significant number of manufacturing plants in the United States, Europe, Israel, Japan and India in connection with a restructuring plan and our ongoing efforts to consolidate our manufacturing and supply network.” 10-K for 2024
Our summaryTeva announced Transformation programs in May 2025 to save costs, including by reducing headcount, and its workforce shrank in 2025 as a result.
Word for word“Under the Teva Transformation programs announced on May 7, 2025, we expect to achieve cost savings through a variety of initiatives including examining practices and efficiencies in methods of working, reduction in headcount and optimizing external spend.” 10-K for 2025
| Fiscal year ended | Restructuring charges |
|---|---|
| 2016-12-31 | $245 million |
| 2017-12-31 | $535 million |
| 2018-12-31 | $488 million |
| 2019-12-31 | $199 million |
| 2020-12-31 | $120 million |
| 2021-12-31 | $133 million |
| 2022-12-31 | $146 million |
| 2023-12-31 | $111 million |
| 2024-12-31 | $74 million |
| 2025-12-31 | $225 million |
Teva Pharmaceutical Industries has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Teva Pharmaceutical Industries’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-03. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.